Nicotine's Potential Abuse With Menthol

Yale University logo

Yale University

Status and phase

Completed
Early Phase 1

Conditions

Nicotine Dependence

Treatments

Drug: Nicotine

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT04535362
2U54DA036151-06 (U.S. NIH Grant/Contract)
2000029223

Details and patient eligibility

About

To examine if switching from menthol to non-menthol cigarettes will change the dose-effect curves for positive subjective effects and alleviation of smoking urges as a function of nicotine delivery rate in smokers.

Full description

A placebo-controlled study that will recruit male and female menthol nicotine dependent smokers. Following screening and evaluation as described above, eligible participants will be enrolled in the study which will last about 4 weeks. Eligible, participants will be randomized to menthol or non-menthol smoking condition for 2 weeks (Phase 1) and then will be switched to the alternative condition for another 2 weeks (Phase 2). The smoking condition will be open label. Participants will be provided with free cigarettes in Phases 1 and 2. For the menthol condition, participants will be provided their usual brand of menthol cigarettes and for the non-menthol condition, they will be provided a matched-brand non-menthol cigarette (e.g., Newport Non-Menthol Gold 100s for those who smoke Newport Menthol Gold 100s). In week 2 of each Phase, participants will have a test session. Each session will include 3 infusions in the same order: nicotine (1 mg per 70 kg body weight) delivered over 5 minutes, saline and nicotine (1 mg/ 70 kg) delivered over 2.5 minutes. Once the participants complete the test session, participants will be crossed-over to the alternative treatment. The period between the 2 Phases will not be longer than one week.

Enrollment

18 patients

Sex

All

Ages

21 to 35 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

    1. Female and male smokers, aged 21 to 35 years, who have been smoking tobacco cigarettes for at least a year;
    1. smoke ≥ 5 and less than 20 cigarettes per day;
    1. urine cotinine levels > 100 ng/mL consistent with nicotine intake of an active smoker
    1. not seeking treatment at the time of the study for nicotine dependence;
    1. in good health as verified by medical history, screening examination, and screening laboratory tests;
    1. for women, not pregnant as determined by pregnancy screening, nor breast feeding, and using acceptable birth control methods.

Exclusion criteria

    1. history of major medical or psychiatric disorders that the physician investigator deems as contraindicated for the subject to be in the study;
    1. regular use of psychotropic medication (antidepressants, antipsychotics, or anxiolytics);
    1. current alcohol or substance dependence for any other recreational or prescription drugs other than nicotine;
    1. use of e-cigarettes more than 10 days in the past 30 days;
    1. urine drug screening indicating recent illicit drugs use (with the exception of marijuana).

Trial design

Primary purpose

Health Services Research

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Single Blind

18 participants in 2 patient groups

menthol cigarettes
Active Comparator group
Description:
Will smoke only menthol cigarettes for two weeks
Treatment:
Drug: Nicotine
non menthol cigarettess
Active Comparator group
Description:
Will only smoke non menthol cigarettes for two weeks
Treatment:
Drug: Nicotine

Trial contacts and locations

1

Loading...

Central trial contact

Stacy Minnix, B.S.; Ellen Mitchell, R.N.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems